C94.02 Acute erythroid leukemia, in relapse

Name of the Condition

• Acute erythroid leukemia, in relapse
• ICD-10 Code: C94.02

Summary

Acute erythroid leukemia, in relapse, is a subtype of acute myeloid leukemia (AML) where the rapid proliferation of immature red blood cell precursors (erythroblasts) in the bone marrow recurs after a period of remission. This relapse disrupts normal blood cell production, leading to anemia, thrombocytopenia, and neutropenia. It is classified as a high-grade malignancy with aggressive clinical behavior and requires prompt intervention to manage disease progression.

Causes

The exact cause involves genetic mutations or chromosomal abnormalities in hematopoietic stem cells, leading to uncontrolled proliferation of erythroid precursors. Contributing factors may include prior exposure to chemotherapy or radiation, genetic predispositions, or underlying myelodysplastic syndromes.

Risk Factors

• Prior exposure to chemotherapy or radiation
• History of myelodysplastic syndromes
• Certain genetic syndromes (e.g., Down syndrome)
• Advanced age
• Male gender
• Exposure to benzene or other toxic chemicals

Symptoms

• Severe fatigue or weakness
• Unexplained weight loss
• Fever or recurrent infections
• Easy bruising or bleeding
• Shortness of breath
• Pale skin (pallor)
• Enlarged liver or spleen (hepatosplenomegaly)

Diagnosis

Diagnosis involves a physical examination, followed by blood tests (complete blood count, peripheral smear) to identify abnormal erythroblasts. Bone marrow aspiration and biopsy confirm the presence of relapsed disease by detecting increased erythroblasts and assessing blast cell percentages. Cytogenetic and molecular testing may be used to identify specific mutations or chromosomal abnormalities.

Treatment Options

Treatment typically involves re-induction chemotherapy to achieve remission again, followed by consolidation therapy. Options may include targeted therapies, stem cell transplantation, or enrollment in clinical trials, depending on the patient’s overall health and prior treatment response.

Prognosis and Follow-Up

Prognosis is generally poor due to the aggressive nature of relapsed disease, though outcomes vary based on age, prior treatment response, and genetic factors. Close monitoring with regular blood tests and bone marrow evaluations is essential to detect further relapse or complications.

Complications

• Severe anemia requiring transfusions
• Increased risk of infections due to neutropenia
• Bleeding disorders from thrombocytopenia
• Organ damage from leukemic infiltration
• Treatment-related toxicities (e.g., chemotherapy side effects)

Lifestyle & Prevention

While prevention is not possible, maintaining overall health through balanced nutrition, avoiding known toxins (e.g., benzene), and adhering to recommended cancer screening may support general well-being. Patients in remission should follow up as directed to monitor for relapse.

When to Seek Professional Help

Seek immediate medical attention for symptoms such as uncontrolled bleeding, high fever, severe fatigue, or signs of infection, as these may indicate relapse or treatment complications.

Tips for Medical Coders

Code C94.02 is used for acute erythroid leukemia in relapse. Documentation should clearly indicate the relapse status, including prior remission and evidence of disease recurrence (e.g., bone marrow findings, blast cell percentages). Ensure the diagnosis aligns with clinical criteria for relapsed AML to support accurate coding.